Տամոքսիֆեն (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Տամոքսիֆեն" in Armenian language version.

refsWebsite

Global rank Armenian rank

61nih.gov

4^th place

3^rd place

47doi.org

2^nd place

4^th place

16semanticscholar.org

11^th place

428^th place

14web.archive.org

1^st place

7archive.org

6^th place

6books.google.com

3^rd place

17^th place

2handle.net

102^nd place

2,318^th place

2clincalc.com

3,912^th place

1,857^th place

1cancer.gov

1,684^th place

184^th place

1drugs.com

399^th place

102^nd place

1usatoday.com

41^st place

245^th place

1harvard.edu

18^th place

38^th place

1modernmedicine.com

low place

1europa.eu

68^th place

88^th place

1dnadirect.com

low place

1curetoday.com

low place

1cancerhelp.org.uk

low place

1fda.gov

447^th place

244^th place

1oncogenetics.org

low place

1iss.it

low place

1healthlifeandstuff.com

low place

1cancer.org

3,680^th place

703^rd place

archive.org

Ahmad A, Shahabuddin S, Sheikh S, Kale P, Krishnappa M, Rane RC, Ahmad I (December 2010). «Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects». Clinical Pharmacology and Therapeutics. 88 (6): 814–817. doi:10.1038/clpt.2010.196. PMID 20981001. S2CID 24590365.
Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, և այլք: (February 2008). «Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function». Cancer Research. 68 (3): 826–833. doi:10.1158/0008-5472.CAN-07-2707. PMID 18245484.
Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, և այլք: (March 2003). «Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer». Journal of the National Cancer Institute. 95 (5): 353–361. doi:10.1093/jnci/95.5.353. PMID 12618500.
Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, և այլք: (May 2011). «Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma». Clinical Pharmacology and Therapeutics. 89 (5): 708–717. doi:10.1038/clpt.2011.27. PMID 21451508. S2CID 20082053.
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, և այլք: (October 2009). «Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen». JAMA. 302 (13): 1429–1436. doi:10.1001/jama.2009.1420. PMC 3909953. PMID 19809024.
Jordan VC (October 1993). «Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer». British Journal of Pharmacology. 110 (2): 507–517. doi:10.1111/j.1476-5381.1993.tb13840.x. PMC 2175926. PMID 8242225.
Steiner AZ, Terplan M, Paulson RJ (June 2005). «Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis». Human Reproduction. 20 (6): 1511–1515. doi:10.1093/humrep/deh840. PMID 15845599.

books.google.com

Cano A, Calaf i Alsina J, Duenas-Diez JL, eds. (2006). Selective Estrogen Receptor Modulators a New Brand of Multitarget Drugs. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg. էջ 52. ISBN 9783540347422.
Runnebaum B, Rabe T (2013 թ․ ապրիլի 17). Gynäkologische Endokrinologie und Fortpflanzungsmedizin: Band 1: Gynäkologische Endokrinologie. Springer-Verlag. էջեր 88–. ISBN 978-3-662-07635-4.
Brenner GM, Stevens C (2017 թ․ սեպտեմբերի 28). Brenner and Stevens' Pharmacology E-Book. Elsevier Health Sciences. էջեր 394–. ISBN 978-0-323-39172-6.
DeVita VT, Lawrence TS, Rosenberg SA (2016 թ․ մարտի 18). Prostate and Other Genitourinary Cancers: From Cancer: Principles & Practice of Oncology, 10th edition. Wolters Kluwer Health. էջեր 990–. ISBN 978-1-4963-5421-1.
Chabner BA, Longo DL (2011 թ․ դեկտեմբերի 7). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. էջեր 655–. ISBN 978-1-4511-4820-6.
Cameron R, Feuer G, de la Iglesia F (2012 թ․ դեկտեմբերի 6). Drug-Induced Hepatotoxicity. Springer Science & Business Media. էջեր 565–. ISBN 978-3-642-61013-4.

cancer.gov

«Tamoxifen Citrate». NCI. 2015 թ․ օգոստոսի 26. Արխիվացված օրիգինալից 2016 թ․ հունվարի 4-ին. Վերցված է 2015 թ․ նոյեմբերի 28-ին.

cancer.org

«Known and Probable Carcinogens». American Cancer Society. 2006 թ․ փետրվարի 3. Արխիվացված օրիգինալից 2008 թ․ մարտի 17-ին. Վերցված է 2008 թ․ մարտի 21-ին.

cancerhelp.org.uk

«Breast cancer in men». CancerHelp UK. Cancer Research UK. 2007 թ․ սեպտեմբերի 28. Արխիվացված է օրիգինալից 2008 թ․ դեկտեմբերի 1-ին. Վերցված է 2009 թ․ մարտի 22-ին.

clincalc.com

«The Top 300 of 2020». ClinCalc. Վերցված է 2022 թ․ հոկտեմբերի 7-ին.
«Tamoxifen Citrate - Drug Usage Statistics». ClinCalc. Արխիվացված է օրիգինալից 2020 թ․ սեպտեմբերի 22-ին. Վերցված է 2022 թ․ հոկտեմբերի 7-ին.

curetoday.com

Staff Reports (Summer 2009). «ASCO Updates: Antidepressants Reduce the Effectiveness of Tamoxifen». CURE (Cancer Updates, Research and Education). Արխիվացված օրիգինալից 2009 թ․ հունիսի 22-ին.

dnadirect.com

talk.dnadirect.com

Information about CYP2D6 and tamoxifen from DNADirect's website Արխիվացված 11 Մարտ 2007 Wayback Machine

doi.org

Quirke VM (2017 թ․ սեպտեմբերի 12). «Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation». Frontiers in Pharmacology. 8: 620. doi:10.3389/fphar.2017.00620. PMC 5600945. PMID 28955226.
Jordan VC (January 2006). «Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer». British Journal of Pharmacology. 147 (Suppl 1): S269–S276. doi:10.1038/sj.bjp.0706399. PMC 1760730. PMID 16402113.
Jordan VC (March 2003). «Tamoxifen: a most unlikely pioneering medicine». Nature Reviews. Drug Discovery. 2 (3): 205–213. doi:10.1038/nrd1031. PMID 12612646. S2CID 31333174.
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL (December 1998). «The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen». Cell. 95 (7): 927–937. doi:10.1016/S0092-8674(00)81717-1. PMID 9875847. S2CID 10265320.
Wang DY, Fulthorpe R, Liss SN, Edwards EA (February 2004). «Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1». Molecular Endocrinology. 18 (2): 402–411. doi:10.1210/me.2003-0202. PMID 14605097.
Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, և այլք: (September 2007). «Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts». Cell. 130 (5): 811–823. doi:10.1016/j.cell.2007.07.025. PMID 17803905. S2CID 17177462.
Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M (February 2008). «Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival». The EMBO Journal. 27 (3): 535–545. doi:10.1038/sj.emboj.7601984. PMC 2241656. PMID 18219273.
Mincey BA, Moraghan TJ, Perez EA (August 2000). «Prevention and treatment of osteoporosis in women with breast cancer». Mayo Clinic Proceedings. 75 (8): 821–829. doi:10.4065/75.8.821. PMID 10943237.
Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE (November 2013). «PharmGKB summary: tamoxifen pathway, pharmacokinetics». Pharmacogenetics and Genomics. 23 (11): 643–647. doi:10.1097/FPC.0b013e3283656bc1. PMC 4084801. PMID 23962908.
Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes DJ, Gelderblom H, Guchelaar HJ (June 2019). «Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen». Expert Review of Clinical Pharmacology. 12 (6): 523–536. doi:10.1080/17512433.2019.1610390. PMID 31008668.
Ahmad A, Shahabuddin S, Sheikh S, Kale P, Krishnappa M, Rane RC, Ahmad I (December 2010). «Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects». Clinical Pharmacology and Therapeutics. 88 (6): 814–817. doi:10.1038/clpt.2010.196. PMID 20981001. S2CID 24590365.
Binkhorst L, Mathijssen RH, Jager A, van Gelder T (March 2015). «Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping». Cancer Treatment Reviews. 41 (3): 289–299. doi:10.1016/j.ctrv.2015.01.002. PMID 25618289.
Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M (December 2000). «Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription». Cell. 103 (6): 843–852. doi:10.1016/S0092-8674(00)00188-4. PMID 11136970. S2CID 6659079.
Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, և այլք: (February 2008). «Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function». Cancer Research. 68 (3): 826–833. doi:10.1158/0008-5472.CAN-07-2707. PMID 18245484.
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, և այլք: (December 2008). «Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen». Nature. 456 (7222): 663–666. Bibcode:2008Natur.456..663H. doi:10.1038/nature07483. PMC 2920208. PMID 19005469.
Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, և այլք: (March 2003). «Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer». Journal of the National Cancer Institute. 95 (5): 353–361. doi:10.1093/jnci/95.5.353. PMID 12618500.
Li J, Ma Z, Jiang RW, Wu B (September 2013). «Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs». Expert Opinion on Drug Metabolism & Toxicology. 9 (9): 1085–1095. doi:10.1517/17425255.2013.802771. PMID 23687971. S2CID 26846314.
Fabian CJ, Kimler BF (March 2005). «Selective estrogen-receptor modulators for primary prevention of breast cancer». Journal of Clinical Oncology. 23 (8): 1644–1655. doi:10.1200/JCO.2005.11.005. PMID 15755972.
Duarte FH, Jallad RS, Bronstein MD (November 2016). «Estrogens and selective estrogen receptor modulators in acromegaly». Endocrine. 54 (2): 306–314. doi:10.1007/s12020-016-1118-z. PMID 27704479. S2CID 10136018.
Morello KC, Wurz GT, DeGregorio MW (2003). «Pharmacokinetics of selective estrogen receptor modulators». Clinical Pharmacokinetics. 42 (4): 361–372. doi:10.2165/00003088-200342040-00004. PMID 12648026. S2CID 13003168.
Prossnitz ER, Arterburn JB (July 2015). «International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators». Pharmacological Reviews. 67 (3): 505–540. doi:10.1124/pr.114.009712. PMC 4485017. PMID 26023144.
Ariazi EA, Jordan VC (2006). «Estrogen-related receptors as emerging targets in cancer and metabolic disorders». Current Topics in Medicinal Chemistry. 6 (3): 203–215. doi:10.2174/1568026610606030203. PMID 16515477.
Liu J, Flockhart PJ, Lu D, Lv W, Lu WJ, Han X, և այլք: (September 2013). «Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen». Drug Metabolism and Disposition. 41 (9): 1715–1720. doi:10.1124/dmd.113.052506. PMC 3876808. PMID 23824607.
Zarate CA, Manji HK (2009). «Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder». CNS Drugs. 23 (7): 569–582. doi:10.2165/00023210-200923070-00003. PMC 2802274. PMID 19552485.
Nagar S (2010). «Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy». Advances in Experimental Medicine and Biology. 678: 124–132. doi:10.1007/978-1-4419-6306-2_16. ISBN 978-1-4419-6305-5. PMID 20738014. S2CID 12537667.
Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, և այլք: (April 2004). «Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial». Clinical Cancer Research. 10 (7): 2336–2343. doi:10.1158/1078-0432.ccr-03-0538. PMID 15073109.
Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, և այլք: (May 2011). «Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma». Clinical Pharmacology and Therapeutics. 89 (5): 708–717. doi:10.1038/clpt.2011.27. PMID 21451508. S2CID 20082053.
Jordan VC (1982). «Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance». Breast Cancer Research and Treatment. 2 (2): 123–138. doi:10.1007/BF01806449. PMID 6184101. S2CID 25119313.
Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, և այլք: (December 2005). «Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes». Journal of Clinical Oncology. 23 (36): 9312–9318. doi:10.1200/JCO.2005.03.3266. PMID 16361630.
Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD (September 2007). «CYP2D6 polymorphisms and the impact on tamoxifen therapy». Journal of Pharmaceutical Sciences. 96 (9): 2224–2231. doi:10.1002/jps.20892. PMID 17518364.
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, և այլք: (October 2009). «Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen». JAMA. 302 (13): 1429–1436. doi:10.1001/jama.2009.1420. PMC 3909953. PMID 19809024.
Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, և այլք: (January 2005). «CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment». Journal of the National Cancer Institute. 97 (1): 30–39. doi:10.1093/jnci/dji005. PMID 15632378.
Thomas B, Magos A (2009). «Modern management of dysmenorrhoea». Trends in Urology, Gynaecology & Sexual Health. 14 (5): 25–29. doi:10.1002/tre.120.
Jordan VC (October 1993). «Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer». British Journal of Pharmacology. 110 (2): 507–517. doi:10.1111/j.1476-5381.1993.tb13840.x. PMC 2175926. PMID 8242225.
Romero SA, Young K, Hickey M, Su HI (December 2020). «Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen». The Cochrane Database of Systematic Reviews. 12 (2): CD007245. doi:10.1002/14651858.CD007245.pub4. PMC 8092675. PMID 33348436.
Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, և այլք: (July 2014). «Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update». Journal of Clinical Oncology. 32 (21): 2255–2269. doi:10.1200/JCO.2013.54.2258. PMC 4876310. PMID 24868023.
Steiner AZ, Terplan M, Paulson RJ (June 2005). «Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis». Human Reproduction. 20 (6): 1511–1515. doi:10.1093/humrep/deh840. PMID 15845599.
Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M (September 2013). «Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis». Andrology. 1 (5): 749–757. doi:10.1111/j.2047-2927.2013.00107.x. PMID 23970453. S2CID 38345293.
Lapid O, van Wingerden JJ, Perlemuter L (2013). «Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review». Journal of Pediatric Endocrinology & Metabolism. 26 (9–10): 803–807. doi:10.1515/jpem-2013-0052. PMID 23729603. S2CID 2101602.
Viani GA, Bernardes da Silva LG, Stefano EJ (July 2012). «Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy?». International Journal of Radiation Oncology, Biology, Physics. 83 (4): e519–e524. doi:10.1016/j.ijrobp.2012.01.036. PMID 22704706.
Neyman A, Eugster EA (December 2017). «Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017». Pediatric Endocrinology Reviews. 15 (2): 136–141. doi:10.17458/per.vol15.2017.nau.treatmentgirlsboys. PMC 5808444. PMID 29292624.
Haddad NG, Eugster EA (June 2019). «Peripheral precocious puberty including congenital adrenal hyperplasia: causes, consequences, management and outcomes». Best Practice & Research. Clinical Endocrinology & Metabolism. 33 (3): 101273. doi:10.1016/j.beem.2019.04.007. hdl:1805/19111. PMID 31027974. S2CID 135410503.
Zacharin M (May 2019). «Disorders of Puberty: Pharmacotherapeutic Strategies for Management». Handbook of Experimental Pharmacology. 261: 507–538. doi:10.1007/164_2019_208. ISBN 978-3-030-50493-9. PMID 31144045. S2CID 169040406.
Esteva FJ, Hortobagyi GN (June 2006). «Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women». Breast. 15 (3): 301–312. doi:10.1016/j.breast.2005.08.033. PMID 16230014.
Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, և այլք: (February 2005). «Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial». Circulation. 111 (5): 650–656. doi:10.1161/01.CIR.0000154545.84124.AC. PMID 15699284.
Harvey HA, Kimura M, Hajba A (April 2006). «Toremifene: an evaluation of its safety profile». Breast. 15 (2): 142–157. doi:10.1016/j.breast.2005.09.007. PMID 16289904.
Osman KA, Osman MM, Ahmed MH (January 2007). «Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?». Expert Opinion on Drug Safety. 6 (1): 1–4. doi:10.1517/14740338.6.1.1. PMID 17181445. S2CID 33505288.

drugs.com

«Tamoxifen Citrate». The American Society of Health-System Pharmacists. Արխիվացված օրիգինալից 2014 թ․ հունվարի 4-ին. Վերցված է 2015 թ․ նոյեմբերի 27-ին.

europa.eu

cordis.europa.eu

«Study sheds new light on tamoxifen resistance». News. CORDIS News. Արխիվացված օրիգինալից 2009 թ․ փետրվարի 20-ին. Վերցված է 2008 թ․ նոյեմբերի 14-ին.

fda.gov

Center for Drug Evaluation and Research (2005 թ․ հուլիսի 7). «Tamoxifen Information: reducing the incidence of breast cancer in women at high risk». U.S. Food and Drug Administration. Արխիվացված է օրիգինալից 2007 թ․ հունիսի 19-ին. Վերցված է 2007 թ․ հուլիսի 3-ին.

handle.net

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Haddad NG, Eugster EA (June 2019). «Peripheral precocious puberty including congenital adrenal hyperplasia: causes, consequences, management and outcomes». Best Practice & Research. Clinical Endocrinology & Metabolism. 33 (3): 101273. doi:10.1016/j.beem.2019.04.007. hdl:1805/19111. PMID 31027974. S2CID 135410503.

harvard.edu

ui.adsabs.harvard.edu

Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, և այլք: (December 2008). «Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen». Nature. 456 (7222): 663–666. Bibcode:2008Natur.456..663H. doi:10.1038/nature07483. PMC 2920208. PMID 19005469.

healthlifeandstuff.com

«Tamoxifen for Breast Cancer & Side Effects». Health and Life. 2009 թ․ դեկտեմբերի 11. Արխիվացված օրիգինալից 2010 թ․ փետրվարի 16-ին.

iss.it

Grilli S (2006). «Tamoxifen (TAM): the dispute goes on» (PDF). Annali dell'Istituto Superiore di Sanità. 42 (2): 170–173. PMID 17033137. Արխիվացված է օրիգինալից (PDF) 2007 թ․ օգոստոսի 10-ին. Վերցված է 2007 թ․ հուլիսի 3-ին.

modernmedicine.com

«New Mechanism Predicts Tamoxifen Response: PAX2 gene implicated in tamoxifen-induced inhibition of ERBB2/HER2-mediated tumor growth». www.modernmedicine.com. 2008 թ․ նոյեմբերի 13. Արխիվացված օրիգինալից 2011 թ․ հուլիսի 14-ին. Վերցված է 2008 թ․ նոյեմբերի 14-ին.

nih.gov

pubmed.ncbi.nlm.nih.gov

Quirke VM (2017 թ․ սեպտեմբերի 12). «Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation». Frontiers in Pharmacology. 8: 620. doi:10.3389/fphar.2017.00620. PMC 5600945. PMID 28955226.
Jordan VC (January 2006). «Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer». British Journal of Pharmacology. 147 (Suppl 1): S269–S276. doi:10.1038/sj.bjp.0706399. PMC 1760730. PMID 16402113.
Jordan VC (March 2003). «Tamoxifen: a most unlikely pioneering medicine». Nature Reviews. Drug Discovery. 2 (3): 205–213. doi:10.1038/nrd1031. PMID 12612646. S2CID 31333174.
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL (December 1998). «The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen». Cell. 95 (7): 927–937. doi:10.1016/S0092-8674(00)81717-1. PMID 9875847. S2CID 10265320.
Wang DY, Fulthorpe R, Liss SN, Edwards EA (February 2004). «Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1». Molecular Endocrinology. 18 (2): 402–411. doi:10.1210/me.2003-0202. PMID 14605097.
Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, և այլք: (September 2007). «Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts». Cell. 130 (5): 811–823. doi:10.1016/j.cell.2007.07.025. PMID 17803905. S2CID 17177462.
Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M (February 2008). «Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival». The EMBO Journal. 27 (3): 535–545. doi:10.1038/sj.emboj.7601984. PMC 2241656. PMID 18219273.
Mincey BA, Moraghan TJ, Perez EA (August 2000). «Prevention and treatment of osteoporosis in women with breast cancer». Mayo Clinic Proceedings. 75 (8): 821–829. doi:10.4065/75.8.821. PMID 10943237.
Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE (November 2013). «PharmGKB summary: tamoxifen pathway, pharmacokinetics». Pharmacogenetics and Genomics. 23 (11): 643–647. doi:10.1097/FPC.0b013e3283656bc1. PMC 4084801. PMID 23962908.
Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes DJ, Gelderblom H, Guchelaar HJ (June 2019). «Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen». Expert Review of Clinical Pharmacology. 12 (6): 523–536. doi:10.1080/17512433.2019.1610390. PMID 31008668.
Ahmad A, Shahabuddin S, Sheikh S, Kale P, Krishnappa M, Rane RC, Ahmad I (December 2010). «Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects». Clinical Pharmacology and Therapeutics. 88 (6): 814–817. doi:10.1038/clpt.2010.196. PMID 20981001. S2CID 24590365.
Binkhorst L, Mathijssen RH, Jager A, van Gelder T (March 2015). «Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping». Cancer Treatment Reviews. 41 (3): 289–299. doi:10.1016/j.ctrv.2015.01.002. PMID 25618289.
Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M (December 2000). «Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription». Cell. 103 (6): 843–852. doi:10.1016/S0092-8674(00)00188-4. PMID 11136970. S2CID 6659079.
Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, և այլք: (February 2008). «Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function». Cancer Research. 68 (3): 826–833. doi:10.1158/0008-5472.CAN-07-2707. PMID 18245484.
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, և այլք: (December 2008). «Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen». Nature. 456 (7222): 663–666. Bibcode:2008Natur.456..663H. doi:10.1038/nature07483. PMC 2920208. PMID 19005469.
Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, և այլք: (March 2003). «Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer». Journal of the National Cancer Institute. 95 (5): 353–361. doi:10.1093/jnci/95.5.353. PMID 12618500.
Li J, Ma Z, Jiang RW, Wu B (September 2013). «Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs». Expert Opinion on Drug Metabolism & Toxicology. 9 (9): 1085–1095. doi:10.1517/17425255.2013.802771. PMID 23687971. S2CID 26846314.
Fabian CJ, Kimler BF (March 2005). «Selective estrogen-receptor modulators for primary prevention of breast cancer». Journal of Clinical Oncology. 23 (8): 1644–1655. doi:10.1200/JCO.2005.11.005. PMID 15755972.
Duarte FH, Jallad RS, Bronstein MD (November 2016). «Estrogens and selective estrogen receptor modulators in acromegaly». Endocrine. 54 (2): 306–314. doi:10.1007/s12020-016-1118-z. PMID 27704479. S2CID 10136018.
Morello KC, Wurz GT, DeGregorio MW (2003). «Pharmacokinetics of selective estrogen receptor modulators». Clinical Pharmacokinetics. 42 (4): 361–372. doi:10.2165/00003088-200342040-00004. PMID 12648026. S2CID 13003168.
Prossnitz ER, Arterburn JB (July 2015). «International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators». Pharmacological Reviews. 67 (3): 505–540. doi:10.1124/pr.114.009712. PMC 4485017. PMID 26023144.
Ariazi EA, Jordan VC (2006). «Estrogen-related receptors as emerging targets in cancer and metabolic disorders». Current Topics in Medicinal Chemistry. 6 (3): 203–215. doi:10.2174/1568026610606030203. PMID 16515477.
Liu J, Flockhart PJ, Lu D, Lv W, Lu WJ, Han X, և այլք: (September 2013). «Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen». Drug Metabolism and Disposition. 41 (9): 1715–1720. doi:10.1124/dmd.113.052506. PMC 3876808. PMID 23824607.
Zarate CA, Manji HK (2009). «Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder». CNS Drugs. 23 (7): 569–582. doi:10.2165/00023210-200923070-00003. PMC 2802274. PMID 19552485.
Nagar S (2010). «Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy». Advances in Experimental Medicine and Biology. 678: 124–132. doi:10.1007/978-1-4419-6306-2_16. ISBN 978-1-4419-6305-5. PMID 20738014. S2CID 12537667.
Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, և այլք: (April 2004). «Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial». Clinical Cancer Research. 10 (7): 2336–2343. doi:10.1158/1078-0432.ccr-03-0538. PMID 15073109.
Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, և այլք: (May 2011). «Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma». Clinical Pharmacology and Therapeutics. 89 (5): 708–717. doi:10.1038/clpt.2011.27. PMID 21451508. S2CID 20082053.
Jordan VC (1982). «Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance». Breast Cancer Research and Treatment. 2 (2): 123–138. doi:10.1007/BF01806449. PMID 6184101. S2CID 25119313.
Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, և այլք: (December 2005). «Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes». Journal of Clinical Oncology. 23 (36): 9312–9318. doi:10.1200/JCO.2005.03.3266. PMID 16361630.
Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD (September 2007). «CYP2D6 polymorphisms and the impact on tamoxifen therapy». Journal of Pharmaceutical Sciences. 96 (9): 2224–2231. doi:10.1002/jps.20892. PMID 17518364.
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, և այլք: (October 2009). «Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen». JAMA. 302 (13): 1429–1436. doi:10.1001/jama.2009.1420. PMC 3909953. PMID 19809024.
Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, և այլք: (January 2005). «CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment». Journal of the National Cancer Institute. 97 (1): 30–39. doi:10.1093/jnci/dji005. PMID 15632378.
Jordan VC (October 1993). «Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer». British Journal of Pharmacology. 110 (2): 507–517. doi:10.1111/j.1476-5381.1993.tb13840.x. PMC 2175926. PMID 8242225.
Romero SA, Young K, Hickey M, Su HI (December 2020). «Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen». The Cochrane Database of Systematic Reviews. 12 (2): CD007245. doi:10.1002/14651858.CD007245.pub4. PMC 8092675. PMID 33348436.
Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, և այլք: (July 2014). «Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update». Journal of Clinical Oncology. 32 (21): 2255–2269. doi:10.1200/JCO.2013.54.2258. PMC 4876310. PMID 24868023.
Steiner AZ, Terplan M, Paulson RJ (June 2005). «Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis». Human Reproduction. 20 (6): 1511–1515. doi:10.1093/humrep/deh840. PMID 15845599.
Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M (September 2013). «Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis». Andrology. 1 (5): 749–757. doi:10.1111/j.2047-2927.2013.00107.x. PMID 23970453. S2CID 38345293.
Lapid O, van Wingerden JJ, Perlemuter L (2013). «Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review». Journal of Pediatric Endocrinology & Metabolism. 26 (9–10): 803–807. doi:10.1515/jpem-2013-0052. PMID 23729603. S2CID 2101602.
Viani GA, Bernardes da Silva LG, Stefano EJ (July 2012). «Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy?». International Journal of Radiation Oncology, Biology, Physics. 83 (4): e519–e524. doi:10.1016/j.ijrobp.2012.01.036. PMID 22704706.
Neyman A, Eugster EA (December 2017). «Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017». Pediatric Endocrinology Reviews. 15 (2): 136–141. doi:10.17458/per.vol15.2017.nau.treatmentgirlsboys. PMC 5808444. PMID 29292624.
Haddad NG, Eugster EA (June 2019). «Peripheral precocious puberty including congenital adrenal hyperplasia: causes, consequences, management and outcomes». Best Practice & Research. Clinical Endocrinology & Metabolism. 33 (3): 101273. doi:10.1016/j.beem.2019.04.007. hdl:1805/19111. PMID 31027974. S2CID 135410503.
Zacharin M (May 2019). «Disorders of Puberty: Pharmacotherapeutic Strategies for Management». Handbook of Experimental Pharmacology. 261: 507–538. doi:10.1007/164_2019_208. ISBN 978-3-030-50493-9. PMID 31144045. S2CID 169040406.
Grilli S (2006). «Tamoxifen (TAM): the dispute goes on» (PDF). Annali dell'Istituto Superiore di Sanità. 42 (2): 170–173. PMID 17033137. Արխիվացված է օրիգինալից (PDF) 2007 թ․ օգոստոսի 10-ին. Վերցված է 2007 թ․ հուլիսի 3-ին.
Esteva FJ, Hortobagyi GN (June 2006). «Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women». Breast. 15 (3): 301–312. doi:10.1016/j.breast.2005.08.033. PMID 16230014.
Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, և այլք: (February 2005). «Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial». Circulation. 111 (5): 650–656. doi:10.1161/01.CIR.0000154545.84124.AC. PMID 15699284.
Harvey HA, Kimura M, Hajba A (April 2006). «Toremifene: an evaluation of its safety profile». Breast. 15 (2): 142–157. doi:10.1016/j.breast.2005.09.007. PMID 16289904.
Osman KA, Osman MM, Ahmed MH (January 2007). «Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?». Expert Opinion on Drug Safety. 6 (1): 1–4. doi:10.1517/14740338.6.1.1. PMID 17181445. S2CID 33505288.

ncbi.nlm.nih.gov

Quirke VM (2017 թ․ սեպտեմբերի 12). «Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation». Frontiers in Pharmacology. 8: 620. doi:10.3389/fphar.2017.00620. PMC 5600945. PMID 28955226.
Jordan VC (January 2006). «Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer». British Journal of Pharmacology. 147 (Suppl 1): S269–S276. doi:10.1038/sj.bjp.0706399. PMC 1760730. PMID 16402113.
Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M (February 2008). «Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival». The EMBO Journal. 27 (3): 535–545. doi:10.1038/sj.emboj.7601984. PMC 2241656. PMID 18219273.
Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE (November 2013). «PharmGKB summary: tamoxifen pathway, pharmacokinetics». Pharmacogenetics and Genomics. 23 (11): 643–647. doi:10.1097/FPC.0b013e3283656bc1. PMC 4084801. PMID 23962908.
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, և այլք: (December 2008). «Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen». Nature. 456 (7222): 663–666. Bibcode:2008Natur.456..663H. doi:10.1038/nature07483. PMC 2920208. PMID 19005469.
Prossnitz ER, Arterburn JB (July 2015). «International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators». Pharmacological Reviews. 67 (3): 505–540. doi:10.1124/pr.114.009712. PMC 4485017. PMID 26023144.
Liu J, Flockhart PJ, Lu D, Lv W, Lu WJ, Han X, և այլք: (September 2013). «Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen». Drug Metabolism and Disposition. 41 (9): 1715–1720. doi:10.1124/dmd.113.052506. PMC 3876808. PMID 23824607.
Zarate CA, Manji HK (2009). «Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder». CNS Drugs. 23 (7): 569–582. doi:10.2165/00023210-200923070-00003. PMC 2802274. PMID 19552485.
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, և այլք: (October 2009). «Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen». JAMA. 302 (13): 1429–1436. doi:10.1001/jama.2009.1420. PMC 3909953. PMID 19809024.
Jordan VC (October 1993). «Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer». British Journal of Pharmacology. 110 (2): 507–517. doi:10.1111/j.1476-5381.1993.tb13840.x. PMC 2175926. PMID 8242225.
Romero SA, Young K, Hickey M, Su HI (December 2020). «Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen». The Cochrane Database of Systematic Reviews. 12 (2): CD007245. doi:10.1002/14651858.CD007245.pub4. PMC 8092675. PMID 33348436.
Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, և այլք: (July 2014). «Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update». Journal of Clinical Oncology. 32 (21): 2255–2269. doi:10.1200/JCO.2013.54.2258. PMC 4876310. PMID 24868023.
Neyman A, Eugster EA (December 2017). «Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017». Pediatric Endocrinology Reviews. 15 (2): 136–141. doi:10.17458/per.vol15.2017.nau.treatmentgirlsboys. PMC 5808444. PMID 29292624.

pubchem.ncbi.nlm.nih.gov

tamoxifen

oncogenetics.org

OncoGenetics.Org (September 2009). «Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects». OncoGenetics.Org. Արխիվացված է օրիգինալից 2009 թ․ սեպտեմբերի 24-ին. Վերցված է 2009 թ․ սեպտեմբերի 14-ին.

semanticscholar.org

api.semanticscholar.org

Jordan VC (March 2003). «Tamoxifen: a most unlikely pioneering medicine». Nature Reviews. Drug Discovery. 2 (3): 205–213. doi:10.1038/nrd1031. PMID 12612646. S2CID 31333174.
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL (December 1998). «The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen». Cell. 95 (7): 927–937. doi:10.1016/S0092-8674(00)81717-1. PMID 9875847. S2CID 10265320.
Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, և այլք: (September 2007). «Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts». Cell. 130 (5): 811–823. doi:10.1016/j.cell.2007.07.025. PMID 17803905. S2CID 17177462.
Ahmad A, Shahabuddin S, Sheikh S, Kale P, Krishnappa M, Rane RC, Ahmad I (December 2010). «Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects». Clinical Pharmacology and Therapeutics. 88 (6): 814–817. doi:10.1038/clpt.2010.196. PMID 20981001. S2CID 24590365.
Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M (December 2000). «Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription». Cell. 103 (6): 843–852. doi:10.1016/S0092-8674(00)00188-4. PMID 11136970. S2CID 6659079.
Li J, Ma Z, Jiang RW, Wu B (September 2013). «Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs». Expert Opinion on Drug Metabolism & Toxicology. 9 (9): 1085–1095. doi:10.1517/17425255.2013.802771. PMID 23687971. S2CID 26846314.
Duarte FH, Jallad RS, Bronstein MD (November 2016). «Estrogens and selective estrogen receptor modulators in acromegaly». Endocrine. 54 (2): 306–314. doi:10.1007/s12020-016-1118-z. PMID 27704479. S2CID 10136018.
Morello KC, Wurz GT, DeGregorio MW (2003). «Pharmacokinetics of selective estrogen receptor modulators». Clinical Pharmacokinetics. 42 (4): 361–372. doi:10.2165/00003088-200342040-00004. PMID 12648026. S2CID 13003168.
Nagar S (2010). «Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy». Advances in Experimental Medicine and Biology. 678: 124–132. doi:10.1007/978-1-4419-6306-2_16. ISBN 978-1-4419-6305-5. PMID 20738014. S2CID 12537667.
Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, և այլք: (May 2011). «Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma». Clinical Pharmacology and Therapeutics. 89 (5): 708–717. doi:10.1038/clpt.2011.27. PMID 21451508. S2CID 20082053.
Jordan VC (1982). «Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance». Breast Cancer Research and Treatment. 2 (2): 123–138. doi:10.1007/BF01806449. PMID 6184101. S2CID 25119313.
Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M (September 2013). «Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis». Andrology. 1 (5): 749–757. doi:10.1111/j.2047-2927.2013.00107.x. PMID 23970453. S2CID 38345293.
Lapid O, van Wingerden JJ, Perlemuter L (2013). «Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review». Journal of Pediatric Endocrinology & Metabolism. 26 (9–10): 803–807. doi:10.1515/jpem-2013-0052. PMID 23729603. S2CID 2101602.
Haddad NG, Eugster EA (June 2019). «Peripheral precocious puberty including congenital adrenal hyperplasia: causes, consequences, management and outcomes». Best Practice & Research. Clinical Endocrinology & Metabolism. 33 (3): 101273. doi:10.1016/j.beem.2019.04.007. hdl:1805/19111. PMID 31027974. S2CID 135410503.
Zacharin M (May 2019). «Disorders of Puberty: Pharmacotherapeutic Strategies for Management». Handbook of Experimental Pharmacology. 261: 507–538. doi:10.1007/164_2019_208. ISBN 978-3-030-50493-9. PMID 31144045. S2CID 169040406.
Osman KA, Osman MM, Ahmed MH (January 2007). «Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?». Expert Opinion on Drug Safety. 6 (1): 1–4. doi:10.1517/14740338.6.1.1. PMID 17181445. S2CID 33505288.

usatoday.com

Kirk E (2002 թ․ հուլիսի 24). «Dog's tale of survival opens door in cancer research». Health and Behavior. USA Today. Արխիվացված օրիգինալից 2008 թ․ հունիսի 28-ին. Վերցված է 2008 թ․ հունիսի 24-ին.

web.archive.org

«Tamoxifen Citrate». NCI. 2015 թ․ օգոստոսի 26. Արխիվացված օրիգինալից 2016 թ․ հունվարի 4-ին. Վերցված է 2015 թ․ նոյեմբերի 28-ին.
«Tamoxifen Citrate». The American Society of Health-System Pharmacists. Արխիվացված օրիգինալից 2014 թ․ հունվարի 4-ին. Վերցված է 2015 թ․ նոյեմբերի 27-ին.
«Tamoxifen Citrate - Drug Usage Statistics». ClinCalc. Արխիվացված է օրիգինալից 2020 թ․ սեպտեմբերի 22-ին. Վերցված է 2022 թ․ հոկտեմբերի 7-ին.
Kirk E (2002 թ․ հուլիսի 24). «Dog's tale of survival opens door in cancer research». Health and Behavior. USA Today. Արխիվացված օրիգինալից 2008 թ․ հունիսի 28-ին. Վերցված է 2008 թ․ հունիսի 24-ին.
«New Mechanism Predicts Tamoxifen Response: PAX2 gene implicated in tamoxifen-induced inhibition of ERBB2/HER2-mediated tumor growth». www.modernmedicine.com. 2008 թ․ նոյեմբերի 13. Արխիվացված օրիգինալից 2011 թ․ հուլիսի 14-ին. Վերցված է 2008 թ․ նոյեմբերի 14-ին.
«Study sheds new light on tamoxifen resistance». News. CORDIS News. Արխիվացված օրիգինալից 2009 թ․ փետրվարի 20-ին. Վերցված է 2008 թ․ նոյեմբերի 14-ին.
Information about CYP2D6 and tamoxifen from DNADirect's website Արխիվացված 11 Մարտ 2007 Wayback Machine
Staff Reports (Summer 2009). «ASCO Updates: Antidepressants Reduce the Effectiveness of Tamoxifen». CURE (Cancer Updates, Research and Education). Արխիվացված օրիգինալից 2009 թ․ հունիսի 22-ին.
«Breast cancer in men». CancerHelp UK. Cancer Research UK. 2007 թ․ սեպտեմբերի 28. Արխիվացված է օրիգինալից 2008 թ․ դեկտեմբերի 1-ին. Վերցված է 2009 թ․ մարտի 22-ին.
Center for Drug Evaluation and Research (2005 թ․ հուլիսի 7). «Tamoxifen Information: reducing the incidence of breast cancer in women at high risk». U.S. Food and Drug Administration. Արխիվացված է օրիգինալից 2007 թ․ հունիսի 19-ին. Վերցված է 2007 թ․ հուլիսի 3-ին.
OncoGenetics.Org (September 2009). «Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects». OncoGenetics.Org. Արխիվացված է օրիգինալից 2009 թ․ սեպտեմբերի 24-ին. Վերցված է 2009 թ․ սեպտեմբերի 14-ին.
Grilli S (2006). «Tamoxifen (TAM): the dispute goes on» (PDF). Annali dell'Istituto Superiore di Sanità. 42 (2): 170–173. PMID 17033137. Արխիվացված է օրիգինալից (PDF) 2007 թ․ օգոստոսի 10-ին. Վերցված է 2007 թ․ հուլիսի 3-ին.
«Tamoxifen for Breast Cancer & Side Effects». Health and Life. 2009 թ․ դեկտեմբերի 11. Արխիվացված օրիգինալից 2010 թ․ փետրվարի 16-ին.
«Known and Probable Carcinogens». American Cancer Society. 2006 թ․ փետրվարի 3. Արխիվացված օրիգինալից 2008 թ․ մարտի 17-ին. Վերցված է 2008 թ․ մարտի 21-ին.